Baricitinib as Treatment for Coronavirus Disease 2019 (COVID-19): Friend or Foe of the Pancreas?
作者信息
Cerda-Contreras Christopher, Nuzzolo-Shihadeh Laura, Camacho-Ortiz Adrián, Perez-Alba Eduardo
机构信息
Servicio de Medicina Interna, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey Mexico.
Servicio de Infectología, Hospital Universitario Dr. José Eleuterio González, Universidad Autónoma de Nuevo León, Monterrey Mexico.
出版信息
Clin Infect Dis. 2021 Dec 6;73(11):e3977-e3978. doi: 10.1093/cid/ciaa1209.
Abstract
摘要
相似文献
1
Baricitinib as Treatment for Coronavirus Disease 2019 (COVID-19): Friend or Foe of the Pancreas?巴瑞替尼治疗2019冠状病毒病（COVID-19）：胰腺的朋友还是敌人？
Clin Infect Dis. 2021 Dec 6;73(11):e3977-e3978. doi: 10.1093/cid/ciaa1209.
2
Baricitinib: Impact on Coronavirus Disease 2019 (COVID-19) Coagulopathy?巴瑞替尼：对2019冠状病毒病（COVID-19）凝血障碍有何影响？
Clin Infect Dis. 2021 Dec 6;73(11):e3978-e3979. doi: 10.1093/cid/ciaa1208.
3
Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019.巴瑞替尼在中重度 2019 冠状病毒病患者中的应用。
Clin Infect Dis. 2021 Apr 8;72(7):1247-1250. doi: 10.1093/cid/ciaa879.
4
Response to Correspondence: Baricitinib: Impact on Coronavirus Disease 2019 (COVID-19) Coagulopathy? Jorgensen et al.对信件的回复：巴瑞替尼：对2019冠状病毒病（COVID-19）凝血障碍有何影响？约根森等人
Clin Infect Dis. 2021 Dec 6;73(11):e3980-e3981. doi: 10.1093/cid/ciaa1210.
5
Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial.巴瑞替尼：在一项安慰剂对照试验中首个降低新冠肺炎死亡率的免疫调节治疗药物。
Lancet Respir Med. 2021 Dec;9(12):1349-1351. doi: 10.1016/S2213-2600(21)00358-1. Epub 2021 Sep 1.
6
Secondary infections and long-term outcomes among hospitalized elderly and non-elderly patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and treated with baricitinib: a comparative study from the national centre of Hungary.住院的老年和非老年严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 患者接受巴瑞替尼治疗后的继发感染和长期结局：来自匈牙利国家中心的一项比较研究。
Geroscience. 2024 Jun;46(3):2863-2877. doi: 10.1007/s11357-024-01099-y. Epub 2024 Feb 17.
7
Comment on: Gudu T, Stober C, Cope AP et al. Baricitinib set to join the Covid-19 therapeutic arsenal?评论：古杜·T、斯托伯·C、科普·AP等人。巴瑞替尼即将加入新冠治疗武器库？
Rheumatology (Oxford). 2021 Oct 2;60(10):e371. doi: 10.1093/rheumatology/keab386.
8
Effect of baricitinib in patients with coronavirus disease 2019 and respiratory failure: A propensity score-matched retrospective cohort study.巴瑞替尼治疗 COVID-19 合并呼吸衰竭患者的效果：一项倾向评分匹配的回顾性队列研究。
Respir Investig. 2022 May;60(3):418-424. doi: 10.1016/j.resinv.2022.02.004. Epub 2022 Mar 7.
9
Baricitinib Therapy in Covid-19 Pneumonia - An Unmet Need Fulfilled.巴瑞替尼治疗新冠病毒肺炎——满足一项未被满足的需求
N Engl J Med. 2021 Mar 4;384(9):867-869. doi: 10.1056/NEJMe2034982.
10
Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.巴瑞替尼作为2019新型冠状病毒急性呼吸道疾病的潜在治疗方法。
Lancet. 2020 Feb 15;395(10223):e30-e31. doi: 10.1016/S0140-6736(20)30304-4. Epub 2020 Feb 4.
引用本文的文献
1
Pancreatic and Hepatic Injury in COVID-19: A Worse Prognosis in NAFLD Patients?COVID-19 中的胰腺和肝脏损伤：非酒精性脂肪性肝病患者的预后更差？
Biomedicines. 2024 Jan 26;12(2):283. doi: 10.3390/biomedicines12020283.
2
COVID-19 and the Pancreas: A Narrative Review.2019冠状病毒病与胰腺：一篇叙述性综述
Life (Basel). 2022 Aug 23;12(9):1292. doi: 10.3390/life12091292.
3
Review on acute pancreatitis attributed to COVID-19 infection.关于 COVID-19 感染引起的急性胰腺炎的综述。
World J Gastroenterol. 2022 May 21;28(19):2034-2056. doi: 10.3748/wjg.v28.i19.2034.
4
Coronavirus disease 2019 and the pancreas.新型冠状病毒病 2019 与胰腺。
Pancreatology. 2020 Dec;20(8):1567-1575. doi: 10.1016/j.pan.2020.10.035. Epub 2020 Oct 12.
Zotero 插件